Spravato Marketing: How to Reach the Patients Who Actually Qualify
Quick answer: Spravato marketing fails when it chases volume. Spravato has narrow eligibility, so a campaign that brings in lots of general "depression help" enquiries mostly fills your schedule with people who don't qualify. The clinics that win treat marketing as a filter, not a net: they target the specific patient Spravato is approved for, qualify hard before anyone books, and measure treatment starts rather than enquiries. This post explains how.
Why is Spravato marketing different from normal clinic marketing?
Because the patient has to clear a bar before they can be treated at all.
Spravato (esketamine) is FDA-approved for treatment-resistant depression, which means the patient must usually have tried two or more antidepressants without adequate relief. Under the FDA's REMS safety programme, it can only be given in a certified healthcare setting, and the patient is monitored for at least two hours after each dose. Most commercial and government insurance plans cover it, but only with prior authorization.
Every one of those facts changes the marketing. You are not looking for "anyone feeling low." You are looking for a specific person: already diagnosed, already medicated, still not well, and able to come into the clinic regularly. Market wider than that and you pay for clicks from people who can never become patients.
Who is the Spravato patient you should actually target?
The qualifying patient sits inside a tight set of conditions. Your messaging and your targeting should speak to them and quietly screen everyone else out.
Why do Spravato campaigns generate so many unqualified leads?
Because generic depression messaging pulls in everyone, and most of them don't qualify.
Run an ad that says "struggling with depression? we can help" and you will get enquiries. You will also get sixteen-year-olds, people who have never tried medication, people doing fine who just had a bad week, and people who want something they can do at home. Your front desk then spends its week sorting through them to find the few who were ever eligible. We cover the cost of that in Why Your Contact Form Is Costing You Patients.
The fix is not more ad spend. It is tighter targeting at the top and a qualification step before the booking, so only people who clear the Spravato bar reach your calendar.
See what’s costing you patients
Most clinics have three or four fixable gaps quietly losing them patients. See yours.
How do you qualify a Spravato enquiry before they book?
You put the questions your front desk would ask anyway in front of the patient first, as a short survey that replaces the contact form.
A qualification survey asks about diagnosis, prior medications, and whether they can attend in-clinic sessions, before anyone on your team spends a minute on them. Patients who clear the bar go straight to the top of your pipeline. Patients who don't get a respectful answer and a path to a different service, instead of a wasted consult slot. It runs day and night, so the Sunday-evening enquiry is sorted by the time you open on Monday.
This matters more for Spravato than almost any other treatment, precisely because the eligibility rules are strict. A qualification step turns "we got forty enquiries" into "we got nine people who actually qualify," which is the number that fills your chairs.
What should you measure?
Treatment starts, not enquiries. A Spravato enquiry count will always look healthy if your targeting is loose, because loose targeting is cheap. What tells you the marketing is working is how many of those enquiries become patients who complete prior authorization and begin treatment. We pull that argument apart in Enquiries Are the Wrong Number, and it applies doubly here, because the gap between "enquired" and "qualified and authorised" is wider for Spravato than for anything else you offer.
Frequently asked questions
Does insurance cover Spravato?
Most commercial and government plans do, but almost always with prior authorization, which the patient and clinic arrange before treatment. Your marketing should set this expectation early, so patients aren't surprised by the paperwork step.
Can I advertise Spravato by name?
You can market your Spravato service, but ad platforms apply extra scrutiny to prescription treatments and controlled substances, and your messaging has to stay within medical advertising rules. The safer, and usually more effective, approach is to lead with the patient's situation (treatment-resistant depression) rather than pushing the drug name hard.
Why are my Spravato leads such poor quality?
Usually because the targeting and the intake are too broad. Generic depression messaging with a plain contact form pulls in everyone, most of whom don't meet the eligibility criteria. Narrower targeting plus a qualification survey fixes it.
How is marketing Spravato different from marketing IV ketamine?
Spravato is FDA-approved, in-clinic, and usually insurance-covered, while IV ketamine is off-label and almost always cash-pay. That changes who you target and what you say. We break the comparison down in TMS vs Spravato vs IV Ketamine.
See where your Spravato marketing is leaking
Our free scan checks your clinic's online presence and flags what's quietly stopping qualified patients from booking, in plain language, with no call required. It takes about three minutes, and it will show you where tighter targeting and a qualification step would win you more treatment starts.
Recent Posts












